Bullish indicating open at $55-$60, IPO prices at $37
In a recent transaction, Mark L. Pacala, a director at the Oncology Institute, Inc. (NASDAQ:TOI), acquired a significant amount of the company’s stock. According to a filing with the Securities and Exchange Commission, Pacala purchased 90,562 shares of common stock on March 26, 2025, at a price of $1.0417 per share. This acquisition, valued at approximately $94,338, was made through a private placement transaction. The purchase price represents an attractive entry point, as InvestingPro data shows the stock is currently trading below its Fair Value, with the shares up over 250% year-to-date.
In addition to the common stock purchase, Pacala also acquired 42,281 common warrants at a price of $0.1250 each. These transactions were executed through Pacala Enterprises, LLC, an entity under his control. Following these acquisitions, Pacala now holds a total of 224,971 shares of common stock and 42,281 common warrants. The company maintains strong liquidity with a current ratio of 2.15, indicating healthy short-term financial positioning.
The purchases were part of a private placement agreement with the company, which issued units consisting of two shares of common stock and one common warrant. These transactions underscore Pacala’s continued investment and interest in the Oncology Institute, reflecting confidence in the company’s future prospects. For deeper insights into TOI’s valuation and growth potential, InvestingPro subscribers can access exclusive analysis and 10+ additional ProTips about the company’s financial health and market position.
In other recent news, The Oncology Institute reported its Q4 2024 earnings, revealing a net loss despite strategic growth initiatives. The company missed analysts’ expectations, with earnings per share (EPS) at -$0.14 compared to the forecasted -$0.08, and revenue at $100.3 million, falling short of the expected $109.15 million. However, the full-year revenue showed a 21.3% increase, reaching $393 million, although gross profit declined by 9.4% to $54 million. The Oncology Institute also announced strategic expansion into Florida and new service contracts, which have been positively received by investors. The company projects 2025 revenue to be between $460 million and $480 million, expecting to achieve profitability by Q4 2025. Despite the earnings miss, the company experienced a 2.38% increase in aftermarket trading, indicating investor optimism. The Oncology Institute’s CFO, Rob Carter, emphasized the company’s readiness for growth, while CEO Dan Bernick highlighted operational management and market expansion as key focus areas for 2025. Additionally, the company successfully restructured its facility agreement and raised $16.5 million through a private placement to strengthen its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.